Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02775006 | Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma | terminated | Phase 3 | 45 | The Netherlands Cancer InstituteOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | terminated | Phase 3 | 8 | Hoffmann-La RocheINDUSTRY | 14 | Feb 15, 2019 |
| clinicaltrials |
| NCT02162537 | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases(METAL2) | terminated | Phase 3 | 95 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01058759 | Taxotere-Enoxaparin-(ENOXA)-Study | terminated | Phase 3 | 14 | Hannover Medical SchoolOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00096265 | Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer | terminated | Phase 3 | 126 | National Cancer Institute (NCI)NIH | 2 | Mar 9, 2018 | clinicaltrials |
| NCT02134015 | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)(HER3-Lung) | terminated | Phase 3 | 145 | Daiichi SankyoINDUSTRY | 10 | Jan 23, 2018 | clinicaltrials |
| NCT02326285 | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB(NeoIntercal) | terminated | Phase 2 / Phase 3 | 1 | AIO-Studien-gGmbHOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02049151 | Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer(START2) | terminated | Phase 3 | 35 | EMD SeronoINDUSTRY | 2 | Aug 23, 2017 | clinicaltrials |
| NCT00526643 | CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients(CAPPA-2) | terminated | Phase 3 | 57 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01319669 | Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy | terminated | Phase 2 / Phase 3 | 11 | Chinese Society of Lung CancerOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | terminated | Phase 2 / Phase 3 | 222 | TransgeneINDUSTRY | 10 | Jan 5, 2017 | clinicaltrials |
| NCT01377376 | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib(ATTENTION) | terminated | Phase 3 | — | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Dec 7, 2016 | clinicaltrials |
| NCT01015443 | Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population(INSPIRE) | terminated | Phase 3 | 285 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 5 | Oct 26, 2016 | clinicaltrials |
| NCT00190476 | Elderly NSCLC/D vs DP (JCOG0207) | terminated | Phase 3 | 230 | Japan Clinical Oncology GroupOTHER | 1 | Sep 12, 2016 | clinicaltrials |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC(Galaxy 2) | terminated | Phase 3 | 696 | Synta Pharmaceuticals Corp.INDUSTRY | 20 | Jul 1, 2016 | clinicaltrials |
| NCT00345059 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer(DISTAL-2) | terminated | Phase 3 | 84 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT02629848 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 3 | 401 | TakedaINDUSTRY | 0 | Dec 14, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00738881 | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer(MARVEL) | terminated | Phase 3 | 23 | National Cancer Institute (NCI)NIH | 2 | Oct 29, 2015 | clinicaltrials |
| NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | terminated | Phase 3 | 1,450 | AmgenINDUSTRY | 0 | Sep 7, 2015 | clinicaltrials |
| NCT00050336 | Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) | terminated | Phase 3 | 702 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT01444118 | A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients(NSCLC) | terminated | Phase 3 | — | Bioven EuropeINDUSTRY | 1 | Jul 22, 2015 | clinicaltrials |
| NCT01282151 | TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer(TRAIL) | terminated | Phase 3 | 148 | Chonnam National University HospitalOTHER | 1 | Jul 14, 2015 | clinicaltrials |
| NCT01379976 | Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer | terminated | Phase 3 | 107 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Apr 24, 2015 | clinicaltrials |
| NCT00254891 | Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 3 | 828 | PfizerINDUSTRY | 26 | Mar 30, 2015 | clinicaltrials |
| NCT00254904 | Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC | terminated | Phase 3 | 839 | PfizerINDUSTRY | 24 | Mar 30, 2015 | clinicaltrials |
| NCT00535275 | NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy | terminated | Phase 3 | 88 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00633568 | Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer | terminated | Phase 3 | 125 | European Lung Cancer Working PartyOTHER | 4 | Feb 12, 2015 | clinicaltrials |
| NCT01046383 | Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients | terminated | Phase 3 | 16 | Immunotec Inc.INDUSTRY | 1 | Jan 21, 2015 | clinicaltrials |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | terminated | Phase 2 / Phase 3 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00596830 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | terminated | Phase 3 | 681 | PfizerINDUSTRY | 26 | Jan 13, 2014 | clinicaltrials |
| NCT00673049 | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer(NSCLC) | terminated | Phase 3 | 583 | PfizerINDUSTRY | 27 | Jul 24, 2013 | clinicaltrials |
| NCT00442026 | Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC | terminated | Phase 3 | 106 | Hellenic Oncology Research GroupOTHER | 1 | Jun 27, 2012 | clinicaltrials |
| NCT00042315 | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 3 | 490 | QLT Inc.INDUSTRY | 0 | May 23, 2012 | clinicaltrials |
| NCT00437749 | A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | terminated | Phase 3 | 214 | CBA ResearchINDUSTRY | 1 | Sep 9, 2011 | clinicaltrials |
| NCT00234468 | Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC | terminated | Phase 3 | 490 | AstraZenecaINDUSTRY | 1 | May 20, 2011 | clinicaltrials |
| NCT00273507 | Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3 | terminated | Phase 3 | 270 | Rigshospitalet, DenmarkOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00522639 | Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation(FDG-PET lung) | terminated | Phase 3 | 120 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00243204 | Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | terminated | Phase 3 | 400 | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
| NCT00290017 | Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | terminated | Phase 3 | 400 | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Apr 30, 2019source: clinicaltrials